Browse

Elsewhere, Otsuka’s kidney drug hit the goal of a confirmatory trial and Vertex’s CRISPR sickle cell drug secured expanded approval.

The purchase hands Ipsen an experimental medicine in late-stage testing for a virus that often affects kidney transplant patients.

A group of coming decisions could provide important insights into how flexible the agency is willing to be under new leadership.